期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

难辨梭状芽孢杆菌相关性腹泻研究进展 被引量：2

Advances in the Research of Clostridium difficile-associated Diarrhea
暂未订购
导出
摘要 难辨梭状芽孢杆菌是一种革兰阳性肠道病原体。难辨梭状芽孢杆菌相关性腹泻(CDAD)及其引起的假膜性肠炎为消化道多发病。难辨梭状芽孢杆菌可产生毒素A和毒素B,侵入肠黏膜后引起细胞病变,导致一系列感染相关临床表现。免疫学机制在难辨梭状芽孢杆菌感染相关疾病的发病中起重要作用。本文就CDAD的发病机制、临床表现及其检测和治疗作一综述。 Clostridium difficile is a gram-positive enteric pathogen. Clostridium difficile-associated diarrhea （CDAD） and pseudomembranous enteritis, a serious complication of CDAD, are frequently seen in GI clinics. Damage of intestinal mucosa cells induced by toxin A and toxin B of Clostridium difficile is responsible for the clinical manifestations of the disease. Immunologic mechanism plays an important role in the development of Clostridium difficile-associated diseases. The pathogenesis, clinical manifestations, diagnosis and treatment of CDAD were reviewed in this article.
作者 邱敏霞 刘诗
机构地区 华中科技大学同济医学院附属协和医院消化内科
出处 《胃肠病学》 2008年第5期309-311,共3页 Chinese Journal of Gastroenterology
关键词 梭菌 难辨 腹泻 小肠结肠炎 伪膜性 诊断试验 治疗 酵母菌 Clostridium difficile Diarrhea Enterocolitis, Pseudomembranous Diagnostic Tests Therapy Yeasts
分类号 R574.62 [医药卫生—消化系统]
  • 相关文献

参考文献20

  • 1Dodson AP, Borriello SP. Clostridium diffwile infection of the gut. J Clin Pathol, 1996, 49 (7): 529-532.
  • 2Pechine S, Janoir C, Collignon A. Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficileassociated disease. J Clin Microbiol, 2005, 43 (10): 5018-5025.
  • 3Govind R, Vediyappan G, Rolfe RD, et al. Evidence that Clostridium difficile TcdC is a membrane-associated protein. J Bacteriol, 2006, 188 (10): 3716-3720.
  • 4Jenkins L. The prevention of Clostridium difficile associated diarrhoea in hospital. Nurs Times, 2004, 100 (26): 56-57, 59.
  • 5沈秋生.难辨梭状芽孢杆菌致伪膜性肠炎的诊治现状[J].抗感染药学,2004,1(3):101-102. 被引量：8
  • 6Lemee L, Dhalluin A, Testelin S, et al. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol, 2004, 42 (12): 5710-5714.
  • 7van den Berg RJ, Bruijnesteijn van Coppenraet LS, Gerritsen HJ, et al. Prospective muhicenter evaluation of a new immunoassay and real-time PCR for rapid diagnosis of Clostridium difficile-associated diarrhea in hospitalized patients. J Clin Microbiol, 2005, 43 (10): 5338-5340.
  • 8关宏,钱家鸣,陆星华,杨晓鸥.用PCR方法检测粪便难辨梭状芽胞杆菌[J].临床消化病杂志,2001,13(4):147-148. 被引量：4
  • 9Zheng L, Keller SF, Lyerly DM, et al. Multicenter evaluation of a new screening test that detects Clostridium difficile in fecal specimens. J Clin Microbiol, 2004, 42 (8): 3837-3840.
  • 10Ticehurst JR, Aird DZ, Dam LM, et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol, 2006, 44 (3): 1145-1149.

二级参考文献29

  • 1[4]Borriello SP. Pathogenesis of Clostridium difficile infection[J]. J Antimicrob Chemother ,1998;41Suppl C:13～19.
  • 2[5]Poxton IR, McCoubrey JM, Blair G.The pathogenicity of Clostridium difficile[J]. Clin Microbiol Infect ,2001,7:421～427.
  • 3[6]S.P. Borriello. Pathogenesis of Clostridium difficile infection[J].Joumal of Antimicrobial Chemotherapy ,1998,41Suppl C: 13～19
  • 4[7]Riley TV, O, Neill GL, Bowman RA,et al. Clostridium difficile-associated diarrhoea: epidemiological data from Western Australia[J]. Epidemiol Infect, 1994,113:13～20.
  • 5[8]Hyland M,Ofner-Agostini ME, Miller MA, et al.Nosocomial Clostridium difficile-associated diarrhea in Canada: the results of the Canadian Nosocomial Infection Surveillance Program (CNISP) 1997 NCDAD prevalence surveillance project[J]. Can J Infect Dis, 2001; 12:81 ～88.
  • 6[9]Kyne L,Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile[J]. Clin Infect Dis ,2002,34(3):346～353.
  • 7[10]Susan M. Poutanen, Andrew E. Simor. Clostridium difficile-associated diarrhea in adults[J].CMA J,2004,171 (1): 51～58.
  • 8[11]Miller MA, Hyland M, Ofner-Agostini M, et al.Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals[J]. Infect Control Hosp Epidemiol 2002;Mar;23(3): 137～140.
  • 9[12]Bignardi GE. Risk factors for Clostridium difficile infection[J]. J Hosp Infect, 1998,40:1～15.
  • 10[13]Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review[J].Clin Infect Dis,1993,17:109～113.

共引文献17

同被引文献7

引证文献2

二级引证文献15

胃肠病学
2008年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部